Animal studies use allometric doses between 10 ng/kg and 10 g/kg
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood-brain barrier and enhance neurogenesis
GLP-1 receptor agonists are licensed in the UK for type 2 diabetes mellitus and specific weight management indications, not for cognitive impairment or dementia GLP-1 receptors are present in brain regions involved in memory and learning, prompting research into potential neuroprotective effects Ongoing clinical trials, including studies of semaglutide in Alzheimer's disease, are examining whether these medications benefit cognitive function Common adverse effects include gastrointestinal symptoms
This is an area that we have never been able to treat previously in plastic surgery, making semaglutide and tirzepatide a relevant option for patients who want to lose weight before their procedure
Link to the FDA's statement in comments
The most important step is the one you take next